Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 32

Sort by

Sort Order Select

Journal Articles

Initial phase 1b/2 study results with sonrotoclax (BGB-11417) in combination with carfilzomib and dexamethasone in patients with t(11;14)-positive relapsed/refractory multiple myeloma

Hang Quach, Rakesh Popat, Wenming Chen, Mary Kwok, Andrew Yee, Zhongxing Jiang, Flávia Xavier, Natalie Callander, Man Yuk Ho, Susan Bal, Michael Low, Douglas Sborov, Gabriel Man, Huan Cheng, Adam Idoine, Xin Wang, Amit Agarwal, Binod Dhakal

Blood (2025) 146 (Supplement 1): 102.

https://doi.org/10.1182/blood-2025-102

Published: 2025

Journal Articles

Interim results from a multicenter trial assessing the clinical relevance of copy number aberrations detected by a shallow whole-genome sequencing analysis (LeukoPrint) in multiple myeloma.

Li Gao, Liping Su, Fengyan Jin, Zhongxing Jiang, Jianyu Weng, Baijun Fang, Zhenyu Li, Lin Qiu, Chenyu Ding, Lijuan Zhang, Manqian Li, Yinyin Chang, Wei Gong, Xi Zhang, Shichun Tu

Blood (2025) 146 (Supplement 1): 3982.

https://doi.org/10.1182/blood-2025-3982

Published: 2025

Journal Articles

Beyond the unknown: Leveraging machine learning to predict adverse outcomes in pregnant women with aplastic anemia from a representative nationwide cohort

Blood (2025) 146 (Supplement 1): 1413.

https://doi.org/10.1182/blood-2025-1413

Published: 2025

Journal Articles

Hetrombopag for patients with persistent primary immune thrombocytopenia: A post-hoc analysis of a multicenter, randomized phase Ⅲ Trial

Blood (2025) 146 (Supplement 1): 4812.

https://doi.org/10.1182/blood-2025-4812

Published: 2025

Journal Articles

Phase 3 ESLIM-01 study: Final analysis of efficacy and safety of long-term treatment with sovleplenib in adults with chronic primary immune thrombocytopenia

Blood (2025) 146 (Supplement 1): 843.

https://doi.org/10.1182/blood-2025-843

Published: 2025

Journal Articles

Stratos: An AI-driven biomarker signature for prognostic risk stratification in transplant-associated thrombotic microangiopathy - a nationwide, multicenter study

Blood (2025) 146 (Supplement 1): 120.

https://doi.org/10.1182/blood-2025-120

Published: 2025

Journal Articles

Efficacy and tolerability of mesutoclax monotherapy in Relapsed/Refractory Mantle Cell Lymphoma patients: High remission rates even in prior BTKi-refractory patients

Blood (2025) 146 (Supplement 1): 887.

https://doi.org/10.1182/blood-2025-887

Published: 2025

Journal Articles

Efficacy and safety of gecacitinib in thrombocytopenic myelofibrosis patients

Blood (2025) 146 (Supplement 1): 2028.

https://doi.org/10.1182/blood-2025-2028

Published: 2025

Journal Articles

The Impact of Anti-HLA Antibodies on the Prognosis of Allogeneic Hematopoietic Stem Cell Transplantation in Myelodysplastic Syndrome

Tiantian Xie, Runqing Lu, Weijie Cao, Bian Zhilei, Wei Li, Zhongxing Jiang, Yongping Song, Dengju Li, Rong Guo

Blood (2024) 144 (Supplement 1): 7419.

https://doi.org/10.1182/blood-2024-206974

Published: 2024

Journal Articles

Antithymocyte Globulin Enhances Myeloid-Derived Suppressor Cell Expansion and Function in Severe Aplastic Anemia

Peiyuan Dong, Yilin Liu, Zhongxing Jiang, Huimin Sun, Yanhong Zhao, Linjie Wu, Jiali Huo, Jing Zhang, Meili Ge, Fang Dong, Sha Hao, Tao Cheng

Blood (2024) 144 (Supplement 1): 4073.

https://doi.org/10.1182/blood-2024-202325

Published: 2024

Journal Articles

SLC25A21 Correlates with the Prognosis of Adult Acute Myeloid Leukemia through Inhibiting the Growth of Leukemia Cells Via Downregulating CXCL8

Shujuan Wang, Yu Liu, Yan Xu, Qianqian Hao, Luyao Shi, Yufei Chen, Yajun Liu, Mengya Li, Yu Zhang, Tao Li, Yafei Li, Zhongxing Jiang, Yanfang Liu, Chong Wang, Bian Zhilei, Lu Yang, Wenyi Lu

Blood (2024) 144 (Supplement 1): 6133.

https://doi.org/10.1182/blood-2024-199630

Published: 2024

Journal Articles

Decoding the Immune Microenvironment of Primary Chronic Myelomonocytic Leukemia and Secondary Chronic Myelomonocytic Leukemia Due to DLBCL with CD19 CAR-T Failure By Single-Cell RNA-Seq

Xudong Li, Hong Huang, Binglei Zhang, Zhongxing Jiang, Yongping Song, Wenyi Lu, Bian Zhilei, Wei Li, Weijie Cao

Blood (2024) 144 (Supplement 1): 6695.

https://doi.org/10.1182/blood-2024-201202

Published: 2024

Journal Articles

Post Hoc Analysis of Phase III Gecacitinib Clinical Trial Outcomes: Enhanced Understanding and Implications

Blood (2024) 144 (Supplement 1): 3165.

https://doi.org/10.1182/blood-2024-202790

Published: 2024

Journal Articles

Long-Term Sovleplenib Treatment of Adults with Primary Immune Thrombocytopenia in China

Blood (2024) 144 (Supplement 1): 2558.

https://doi.org/10.1182/blood-2024-204447

Published: 2024

Journal Articles

Efficacy and Safety of Clifutinib, a Novel, Highly Selective, Oral FLT3 Inhibitor, in Patients with FLT3-Mutated Relapsed or Refractory Acute Myeloid Leukemia：Updated Results from a Phase I Study

Blood (2023) 142 (Supplement 1): 4281.

https://doi.org/10.1182/blood-2023-188961

Published: 2023

Journal Articles

Long Noncoding RNA NEAT1 Regulates Acute Graft-Versus-Host Disease By Promoting Macrophage M1 Polarization through JNK Pathway

Ran Zhang, Zhenli Huang, Li Wang, Weijie Cao, Donald Small, Ruiqi Zhu, Wei Shi, Zhongxing Jiang, Linghui Xia

Blood (2023) 142 (Supplement 1): 2053.

https://doi.org/10.1182/blood-2023-189758

Published: 2023

Journal Articles

A Phase I/II Trial of the FLT3 Kinase Inhibitor XY0206 in Patients with Relapsed/Refractory Acute Myeloid Leukemia

Junyuan Qi, Lin Song, Xudong Wei, Zhimin Zhai, Anyou Wang, Daozi Jiang, Yang Liang, Fei Li, Zhongxing Jiang, Xuejun Zhang, Qunyi Guo, Hongmei Jing, Yajing Xu, Xiangmin Tong, Jianxiang Wang

Blood (2023) 142 (Supplement 1): 2908.

https://doi.org/10.1182/blood-2023-183088

Published: 2023

Journal Articles

The Combination of Iguratimod and Danazol Versus Danazol As a Treatment of Corticosteroid-Resistant/Relapse Immune Thrombocytopenia: A Randomized, Controlled, Multicenter, Open-Label Trial

Xiaolu Zhu, Hui Liu, Zhao Wang, Zhongxing Jiang, Liangming Ma, Min Wang, Jiamin Zhang, Zhuoyu An, Yejun Wu, Yun He, Haixia Fu, Yingjun Chang, Lanping Xu, Kaiyan Liu, Xiao Jun Huang, Xiaohui Zhang

Blood (2023) 142 (Supplement 1): 2589.

https://doi.org/10.1182/blood-2023-184342

Published: 2023

Journal Articles

Humanized Monoclonal Antibody IMM47, Targeting CD24, Exhibits Exceptional Anti-Tumor Efficacy By Blocking the CD24/Siglec-10 Interaction and Can be Used As Monotherapy or in Combination with Anti-PD1 Antibodies for Cancer Immunotherapy

Jifeng Yu, Song Li, Dianze Chen, Huiqin Guo, Yanan Yang, Dandan Liu, Chunmei Yang, Xing Bai, Wei Zhang, Li Zhang, Gui Zhao, Xiaoping Tu, Liang Peng, Sijin Liu, Yongping Song, Zhongxing Jiang, Ruliang Zhang, Wenzhi Tian

Blood (2023) 142 (Supplement 1): 7140.

https://doi.org/10.1182/blood-2023-172483

Published: 2023

Journal Articles

ZGGS15, a Novel IgG4 Bispecific Monoclonal Antibody Targeting Both LAG-3 and Tigit, Demonstrates Outstanding Anti-Tumor Activity and Can be Used As Monotherapy or in Combination with Anti-PD-1 Antibodies for Cancer Immunotherapy

Jifeng Yu, Tongcheng Dai, Hao Sun, Bin Zhang, Tyler Liban, Jessica Ochoa, Jackie Sheng, Yongping Song, Zhongxing Jiang, Zelin Sheng, Binhua Lv

Blood (2023) 142 (Supplement 1): 5764.

https://doi.org/10.1182/blood-2023-184775

Published: 2023

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

Initial phase 1b/2 study results with sonrotoclax (BGB-11417) in combination with carfilzomib and dexamethasone in patients with t(11;14)-positive relapsed/refractory multiple myeloma

Interim results from a multicenter trial assessing the clinical relevance of copy number aberrations detected by a shallow whole-genome sequencing analysis (LeukoPrint) in multiple myeloma.

Beyond the unknown: Leveraging machine learning to predict adverse outcomes in pregnant women with aplastic anemia from a representative nationwide cohort

Hetrombopag for patients with persistent primary immune thrombocytopenia: A post-hoc analysis of a multicenter, randomized phase Ⅲ Trial

Phase 3 ESLIM-01 study: Final analysis of efficacy and safety of long-term treatment with sovleplenib in adults with chronic primary immune thrombocytopenia

Stratos: An AI-driven biomarker signature for prognostic risk stratification in transplant-associated thrombotic microangiopathy - a nationwide, multicenter study

Efficacy and tolerability of mesutoclax monotherapy in Relapsed/Refractory Mantle Cell Lymphoma patients: High remission rates even in prior BTKi-refractory patients

Efficacy and safety of gecacitinib in thrombocytopenic myelofibrosis patients

The Impact of Anti-HLA Antibodies on the Prognosis of Allogeneic Hematopoietic Stem Cell Transplantation in Myelodysplastic Syndrome

Antithymocyte Globulin Enhances Myeloid-Derived Suppressor Cell Expansion and Function in Severe Aplastic Anemia

SLC25A21 Correlates with the Prognosis of Adult Acute Myeloid Leukemia through Inhibiting the Growth of Leukemia Cells Via Downregulating CXCL8

Decoding the Immune Microenvironment of Primary Chronic Myelomonocytic Leukemia and Secondary Chronic Myelomonocytic Leukemia Due to DLBCL with CD19 CAR-T Failure By Single-Cell RNA-Seq

Post Hoc Analysis of Phase III Gecacitinib Clinical Trial Outcomes: Enhanced Understanding and Implications

Long-Term Sovleplenib Treatment of Adults with Primary Immune Thrombocytopenia in China

Efficacy and Safety of Clifutinib, a Novel, Highly Selective, Oral FLT3 Inhibitor, in Patients with FLT3-Mutated Relapsed or Refractory Acute Myeloid Leukemia：Updated Results from a Phase I Study

Long Noncoding RNA NEAT1 Regulates Acute Graft-Versus-Host Disease By Promoting Macrophage M1 Polarization through JNK Pathway

A Phase I/II Trial of the FLT3 Kinase Inhibitor XY0206 in Patients with Relapsed/Refractory Acute Myeloid Leukemia

The Combination of Iguratimod and Danazol Versus Danazol As a Treatment of Corticosteroid-Resistant/Relapse Immune Thrombocytopenia: A Randomized, Controlled, Multicenter, Open-Label Trial

Humanized Monoclonal Antibody IMM47, Targeting CD24, Exhibits Exceptional Anti-Tumor Efficacy By Blocking the CD24/Siglec-10 Interaction and Can be Used As Monotherapy or in Combination with Anti-PD1 Antibodies for Cancer Immunotherapy

ZGGS15, a Novel IgG4 Bispecific Monoclonal Antibody Targeting Both LAG-3 and Tigit, Demonstrates Outstanding Anti-Tumor Activity and Can be Used As Monotherapy or in Combination with Anti-PD-1 Antibodies for Cancer Immunotherapy

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only